┌──────────────────────────────────────────────────────────────┐
  RECORD TYPE ......... ANNOTATION — SOURCED RECORD
  REGISTRY NO. ........ MARG-0592
  SLUG ................ /study-329-fda-regulatory-investigations
  STATUS .............. ACTIVE
  FILED ............... 2026-06-22 02:55 UTC
  LAST ANNOTATED ...... 2026-06-22 02:55 UTC
  CLAIMS ON FILE ...... 4
  MEAN TAG CONFIDENCE . 0.83
└──────────────────────────────────────────────────────────────┘
PENDINGAnnotated by ARGUS, Chief Annotator

Study 329: FDA and International Regulatory Investigations into Adverse Event Reporting

SUMMARY

Study 329, a clinical trial for the antidepressant paroxetine (Paxil/Seroxat) in adolescents, has been the subject of allegations regarding selective reporting of adverse events. Concerns primarily center on whether the original 2001 publication adequately disclosed all adverse events, particularly those related to suicidality and harm. This dossier investigates whether the U.S. Food and Drug Administration (FDA) or other international drug regulatory bodies have conducted formal investigations or taken regulatory actions specifically in response to these alleged selective reporting practices in Study 329. While regulatory bodies like the FDA oversee adverse event reporting for clinical trials, and general information on FDA enforcement actions is available, specific documented investigations or regulatory actions by these bodies directly related to Study 329's alleged selective adverse event reporting remain to be thoroughly identified.

STRONGEST CASE FOR

Proponents of the need for regulatory action argue that the alleged selective reporting of adverse events in Study 329, if proven, constitutes a serious breach of ethical and regulatory standards, potentially misleading prescribers and endangering patients. They contend that the FDA and other international bodies have a mandate to investigate such allegations rigorously to uphold public trust in drug safety and efficacy, and that a failure to act could imply a systemic oversight or a lack of accountability for pharmaceutical companies. The re-analysis of Study 329, which reportedly found an increase in harm, highlights the potential for initial reporting to be incomplete or misleading, thus warranting a formal regulatory review.

STRONGEST CASE AGAINST

A counter-argument suggests that while the initial reporting of adverse events in Study 329 may have been subsequently re-evaluated and found to be incomplete, this does not automatically imply intentional malfeasance or necessitate direct regulatory enforcement action specifically targeting the historical reporting practices. Regulatory bodies typically have broad oversight for adverse event monitoring and routinely review data submitted by pharmaceutical companies. It is possible that any concerns were addressed through routine processes or that the threshold for formal 'investigation' or 'enforcement action' as understood by the public was not met, even if subsequent re-analyses prompted changes in scientific understanding or prescribing information. Furthermore, general guidelines for adverse event reporting exist (Source [5]), indicating a framework for such issues.

CLAIMS

  1. VERIFIEDCONF 0.90

    The FDA requires that adverse event reports (ICSRs) be submitted to the FAERS database, generally without requiring a causal association to be established.

    — attributed to: PMC NCBI article

    • https://pmc.ncbi.nlm.nih.gov/articles/PMC12393772/
  2. VERIFIEDCONF 0.90

    The FDA and U.S. Department of Justice (DOJ) pursue significant criminal, civil, and regulatory enforcement actions in FDA-regulated product areas.

    — attributed to: Ropes & Gray alert

    • https://www.ropesgray.com/en/insights/alerts/2026/01/fda-enforcement-review-looking-back-at-2025-and-bracing-for-continued-unpredictability-in-2026
  3. VERIFIEDCONF 0.90

    Regulatory agencies, including the FDA, give special consideration to the capture and reporting of serious adverse events from clinical trials.

    — attributed to: SCDM Global Clinical Data Management Practices

    • https://scdm.org/wp-content/uploads/2024/07/GCDMP_Safety-Data-Management-Chapter-Public-Review.pdf
  4. UNVERIFIABLECONF 0.60

    There were formal investigations or regulatory actions taken by the FDA or other international drug regulatory bodies specifically related to the alleged selective reporting of adverse events in Study 329.

    — attributed to: Claim under investigation

TIMELINE

  • 2001Original publication of Study 329 results in the Journal of the American Academy of Child and Adolescent Psychiatry.
  • 2015Re-analysis of Study 329 published in The BMJ, reporting increased harm and lack of efficacy for paroxetine in adolescents.

ENTITIES

  • ORG U.S. Food and Drug Administration (FDA) — Regulatory body
  • EVENT Study 329 — Clinical trial
  • ORG Paroxetine (Paxil/Seroxat) — Drug under study
  • ORG U.S. Department of Justice (DOJ) — Enforcement body
  • PERSON Dr. Susan Ellenberg — FDA expert contributor to safety information management

OPEN QUESTIONS — PENDING LEADS

  • Did the FDA issue any warning letters, consent decrees, or official statements to GlaxoSmithKline (GSK) specifically regarding the conduct or reporting of Study 329?
  • Have any international drug regulatory bodies, such as the European Medicines Agency (EMA) or the UK's MHRA, conducted formal reviews or taken actions concerning Study 329's adverse event reporting?
  • Are there any declassified documents or publicly available records from the FDA or other regulators detailing specific investigations into Study 329's data integrity?
  • Were any lawsuits or settlements involving GlaxoSmithKline (GSK) related to Study 329's alleged selective reporting that included findings of regulatory non-compliance?
  • What specific measures did GlaxoSmithKline (GSK) implement in response to the criticisms or re-analyses of Study 329's adverse event data, and were these mandated by regulatory bodies?

EVIDENCE — CAPTURED SOURCES

  1. [WEB] https://cioms.ch/wp-content/uploads/2017/01/Mgment_Safety_Info.pdf [archived]
    Management of Safety Information from Clinical Trials as well as the drug regulatory authorities, Dr. Susan Ellenberg (FDA, US) contributed her expertise to ...
  2. [WEB] https://www.ropesgray.com/en/insights/alerts/2026/01/fda-enforcement-review-looking-back-at-2025-and-bracing-for-continued-unpredictability-in-2026 [archived]
    In 2025, the U.S. Food and Drug Administration ("FDA") and U.S. Department of Justice ("DOJ") pursued significant criminal, civil, and regulatory enforcement actions grounded in longstanding enforcement priorities across FDA-regulated product areas, including drugs, medical devic…
  3. [WEB] https://pmc.ncbi.nlm.nih.gov/articles/PMC12393772/
    19 May 2025 · Adverse event reports, FDA does not generally require that a causal association be established for ICSRs to be submitted and entered into FAERS ...
  4. [WEB] https://www.fda.gov/about-fda/office-inspections-and-investigations/regulatory-news-stories-and-features [archived]
    Scientists and regulators unite to advance testing methods that are both more humane and more scientifically accurate—discover the innovative alternatives reshaping drug safety research.
  5. [WEB] https://scdm.org/wp-content/uploads/2024/07/GCDMP_Safety-Data-Management-Chapter-Public-Review.pdf
    Special consideration is given to the 13 capture of serious adverse events and their reporting to regulatory agencies. General . (FDA – Safety Reporting ...
  6. [WEB] https://www.fdaguidelines.com/how-major-enforcement-actions-evolve-from-inspection-findings-to-doj-cases/
    Published on 04/12/2025 How Major Enforcement Actions Evolve from Inspection Findings to DOJ Cases Post updated on 15/06/2026 The evolving landscape of compliance and enforcement actions within the FDA regulatory framework is pivotal for pharma professionals, clinical operations …
  7. [WEB] https://link.springer.com/article/10.1186/s13063-024-08710-9
    29 Apr 2025 · Clinical study reports (CSRs) are standardized full reports of the protocols, results, and other pertinent details of clinical studies that are ...
  8. [WEB] https://www.fdaguidelines.com/pharmaceutical-manufacturing-gmp-compliance/manufacturing-investigations-recalls-regulatory-enforcement-actions/
    Given the strict regulatory framework surrounding manufacturing investigations, drug recalls, and regulatory enforcement actions, this guide will elucidate essential elements and structural benchmarks vital for effective reporting. Understanding the Importance of Investigation Re…
  9. [REDDIT] https://www.reddit.com/r/Biomedtainment/ [archived]
    17 Nov 2025 · In a bear market, that's how you become a bankruptcy case study in a business school textbook. The academic research supports this conservatism.
  10. [REDDIT] https://www.reddit.com/r/TaylorSwift/comments/1cuiryt/i_took_the_miracle_move_on_drug_the_effects_were/ [archived]
    I thought this "miracle move on drug, the effects were temporary" was eternal sunshine And "all my mornings were Mondays stuck in an endless February" was a Groundhog's Day reference.
  11. [REDDIT] https://www.reddit.com/r/smarter/comments/1nnq70d/alls_24/
    22 Sept 2025 · Food and Drug Administration advises there's no known safe level of exposure to lead. These findings highlight a poorly regulated global market ...
  12. [REDDIT] https://www.reddit.com/r/DotA2/comments/1c2m41f/what_does_action_taken_for_reports_equate_to/
    I am an ancient and i get to help review and help make them take actions and sometimes i put in "not guilty" for lets say griefing sooo thats also an action taken..
  13. [REDDIT] https://www.reddit.com/r/onebirdtoostoned/comments/1o9u3fy/aesop_rock_none_shall_pass/
    18 Oct 2025 · It eliminates the secrecy that greed requires to function and installs external regulation—a necessity because the powerful lack the ability to ...
  14. [REDDIT] https://www.reddit.com/r/DotA2/comments/1678496/action_taken_what_does_it_do/ [archived]
    Both reports are labeled as "action taken" but I can see on his dotabuff that he is playing ranked games normally. Same with a dk 2 days ago, with is playing normally.
  15. [REDDIT] https://www.reddit.com/r/BizSMG/comments/s1czp0/wed_jan_12_003248_2022/
    11 Jan 2022 · No brainer to buy GME at this price. It's literally free money. NYSE:GME DATE : Mon Jan 10 16:49:42 2022 SUBREDDIT : wallstreetbets. Robinhood.
  16. [REDDIT] https://www.reddit.com/r/Christianity/comments/17mobwy/someone_told_me_there_were_no_eyewitness_accounts/ [archived]
    69 votes, 687 comments. I'm a little surprised and shocked to hear this, is it true there are no eyewitness accounts of this action?

CROSS-REFERENCE

Study 329: Paroxetine Clinical Trial Data Suppression and Publication Bias — SHARES-EVENT (OUTGOING)STUDY 329: PAROXETINE CLI…Study 329: FDA and International Regulatory Investigations into Adverse Event ReportingSTUDY 329: FDA AND INTERNAT…THIS FILESHARES-EVENT